Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00095212 · ClinicalTrials.gov registry record · NA

Androgen Effects in HIV-infected Women

A NA study of HIV Infection, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
25
Enrollment target
1
Study location

NCT00095212 is a NA study of HIV Infection that has completed, run by Massachusetts General Hospital. The registered enrollment target is 25 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00095212, a NA study of HIV Infection, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

Androgen deficiency in HIV-infected women is associated with sarcopenia and may cause critical reductions in physical functioning and reduced bone density. The effects of long-term androgen therapy on lean body mass, bone density and other clinical endpoints including quality of life, functional status and neurocognitive function in HIV-infected women are not known.

Conditions Studied

Interventions

  • DRUG 1 Transdermal Testosterone (Patch)
  • DRUG 2 Placebo Patch

Study Locations (1)

Massachusetts

  • Mass General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2004-09
Est. Completion 2009-02
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT00095212

The ClinicalTrials.gov registry entry for NCT00095212 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (90% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 2 interventions - of which 1 Transdermal Testosterone (Patch) is the first listed.

NCT00095212 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00095212 about?

NCT00095212 is a clinical study titled "Androgen Effects in HIV-infected Women". Androgen deficiency in HIV-infected women is associated with sarcopenia and may cause critical reductions in physical functioning and reduced bone density. The effects of long-term androgen therapy on lean body mass, bone density and other clinical endpoints including quality of life, functional sta...

What is the current status of trial NCT00095212?

This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2004-09. Estimated completion is 2009-02.

What conditions does trial NCT00095212 study?

This clinical trial studies the following conditions: HIV Infection.

What interventions are being tested in trial NCT00095212?

The interventions under investigation include: 1 Transdermal Testosterone (Patch) (DRUG), 2 Placebo Patch (DRUG).

Who is sponsoring clinical trial NCT00095212?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00095212 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.